5 completed, 3 terminated, 1 recruiting, 1 withdrawn. 9 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Terminated 2, Recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Marginal Zone B-Cell Lymphoma: new trials by email Literature Review of Marginal Zone B-Cell Lymphoma trials Research Report on Marginal Zone B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders HSCT with TBI Regimen, HSCT with Non-TBI Regimen - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 300 | 2018-03-30 | 2026-06-25 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Fludarabine, Cyclophosphamide, MMF - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 15 | 2017-05-15 | 2025-07-04 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies Infusion of Treg - Acute Lymphoblastic Leukemia, Burkitt Lymphoma | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 3 | 2017-02-16 | 2020-09-29 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Fludarabine, Cyclophosphamide, Total Body Irradiation - Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 200 | 2016-12-01 | 2026-05-20 |
| Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) bendamustine plus rituximab - Marginal Zone B-cell Lymphoma | Phase 2 | Completed | Seoul National University Hospital | 27 | 2015-05-01 | 2026-04-22 |
| A Phase II Study of Doxycycline in Relapsed NHL Doxycycline - Adult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent | Phase 2 | Terminated | University of Rochester | 7 | 2014-03-01 | 2016-12-22 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Treg cells, CD3+ Teff cells, Fludarabine - Hematologic Malignancy, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2014-01-01 | 2017-12-02 | |
| Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma Bendamustine and Rituximab - Marginal Zone B-cell Lymphoma | Phase 2 | Completed | International Extranodal Lymphoma Study Group (IELSG) | 78 | 2012-07-01 | 2023-02-01 |
| Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) Everolimus - Marginal Zone B-cell Lymphoma | Phase 2 | Completed | International Extranodal Lymphoma Study Group (IELSG) | 30 | 2010-03-01 | 2013-11-25 |
| Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Lenalidomide, Dexamethasone, Rituximab - Follicular Lymphoma, Marginal Zone B-Cell Lymphoma | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 50 | 2008-07-01 | 2023-03-30 |
Lymphoma, B-Cell, Marginal Zone (10) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, Follicular (7) · Lymphoma, Mantle-Cell (6) · Burkitt Lymphoma (5) · Leukemia, Myeloid, Acute (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Prolymphocytic (4) · Multiple Myeloma (4) · Anemia, Refractory, with Excess of Blasts (3) · Leukemia, Plasma Cell (3) · Myeloproliferative Disorders (3) · Primary Myelofibrosis (3) · Dendritic Cell Sarcoma, Interdigitating (2)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoma, B-Cell (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Lymphoma (9) · Lymphoma, Non-Hodgkin (8) · Chronic Disease (7) · Disease Attributes (7) · Hematologic Diseases (7) · Leukemia, B-Cell (7) · Leukemia, Lymphoid (7)
Cyclophosphamide (3) · Rituximab (3) · Whole-Body Irradiation (3) · fludarabine (3) · fludarabine phosphate (3) · Bendamustine Hydrochloride (2) · Antilymphocyte Serum (1) · Calcium Dobesilate (1) · Cord Blood Stem Cell Transplantation (1) · Cyclosporine (1) · Dexamethasone (1) · Doxycycline (1) · Everolimus (1) · Hematopoietic Stem Cell Transplantation (1) · Lenalidomide (1)
Masonic Cancer Center, University of Minnesota (5) · International Extranodal Lymphoma Study Group (IELSG) (2) · Abramson Cancer Center at Penn Medicine (1) · Seoul National University Hospital (1) · University of Rochester (1)
United States (7) · Italy (2) · Austria (1) · France (1) · South Korea (1) · Switzerland (1)
Claudio Brunstein, MD, PhD (2) · Annarita Conconi, MD (1) · Carla Casulo, MD (1) · Claudio Brunstein, MD (1) · Dae Seog Heo, MD, PhD (1) · Emanuele Zucca, MD (1) · Emilio Iannitto, MD (1) · Margaret MacMillan, MD, MSC (1) · Punita Grover, MD (1) · Stephen J Schuster, MD (1)
2009 (1)